Page 126 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $6.01
52wk Low $1.15 NRx Pharmaceuticals, Inc. NRXP $2.08
1201 Orange Street
Wilmington, DE 19801

(USD - in millions) www.nrxpharma.com
Market Cap 50.6
Enterprise 53.7
Basic Shares Out. 23.77 COMPANY OVERVIEW
Float 16.00
Institutional Holdings 8.14% Detailed Analysis:Channelchek.com
Short Interest 0.86
Avg. 90-Day Volume 0.47 We are NRx – a pioneering and focused CNS biopharma company,
dedicated to meeting unmet medical needs for those with suicidal
depression, suicidal bipolar depression, and post-traumatic stress
disorder (PTSD).
EPS Data The company has filed an Abbreviated New Drug Application (ANDA)
2022 2023 2024 for NRX-100, preservative-free IV ketamine and has initiated filing of an
CQ1 N/A N/A (0.74) NDA for NRX-100 in people with suicidal depression.
CQ2 N/A N/A (0.75)

CQ3 N/A N/A (0.15)
CQ4 N/A N/A (0.77)
CY N/A N/A (2.36) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) -0.93
ROE (ttm) NM
Debt-to-Total Cap. (mrq) NM
Fiscal Year End 31-Dec
1201 Orange SWilmington DE 19801

Key Executives
CEO: Javitt, Jonathan
CFO: Abrams, Michael
COO: N/A
IR: Messere, Suzanne
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures